BriaCell Therapeutics Corp.
BCT.TO
TSX
| 01/31/2025 | 10/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -0.17% | 3.16% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 39.14% | -10.67% | |||
| Operating Income | -39.14% | 10.67% | |||
| Income Before Tax | -8.72% | -366.79% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -8.72% | -366.79% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 71.22% | -21.68% | |||
| Net Income | -8.43% | -377.86% | |||
| EBIT | -39.14% | 10.67% | |||
| EBITDA | -39.34% | 10.00% | |||
| EPS Basic | 28.66% | -220.63% | |||
| Normalized Basic EPS | 28.78% | -225.31% | |||
| EPS Diluted | 29.38% | -208.30% | |||
| Normalized Diluted EPS | 28.78% | -225.31% | |||
| Average Basic Shares Outstanding | 52.00% | 49.05% | |||
| Average Diluted Shares Outstanding | 52.00% | 49.05% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||